MX2011009224A - Derivados de imidazol utiles como modulares de amida hidrolasa de acido graso y como agentes de formacion de imagenes de amida hidrolasa de cido graso. - Google Patents

Derivados de imidazol utiles como modulares de amida hidrolasa de acido graso y como agentes de formacion de imagenes de amida hidrolasa de cido graso.

Info

Publication number
MX2011009224A
MX2011009224A MX2011009224A MX2011009224A MX2011009224A MX 2011009224 A MX2011009224 A MX 2011009224A MX 2011009224 A MX2011009224 A MX 2011009224A MX 2011009224 A MX2011009224 A MX 2011009224A MX 2011009224 A MX2011009224 A MX 2011009224A
Authority
MX
Mexico
Prior art keywords
faah
modulators
imaging agents
imidazole derivatives
derivatives useful
Prior art date
Application number
MX2011009224A
Other languages
English (en)
Inventor
Linus S Lin
Robert J Devita
Ping Liu
Marc D Chioda
Terence G Hamill
Wenping Li
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2011009224A publication Critical patent/MX2011009224A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La presente invención está dirigida a ciertos derivados de imidazol, los cuales son útiles como moduladores de la amida hidrolasa de ácido graso (FAAH) y como agentes de formación de imágenes de la FAAH; la invención se refiere también a formulaciones farmacéuticas que comprenden estos compuestos como ingredientes activos, y al uso de los compuestos y sus formulaciones en el tratamiento de ciertos trastornos, que incluyen osteoartritis, artritis reumatoide, neuropatía diabética, neuralgia post-herpética, dolor del músculo esquelético y fibromialgia, así como dolor agudo, migraña, trastorno del sueño, enfermedad de Alzheimer y enfermedad de Parkinson.
MX2011009224A 2009-03-04 2010-02-22 Derivados de imidazol utiles como modulares de amida hidrolasa de acido graso y como agentes de formacion de imagenes de amida hidrolasa de cido graso. MX2011009224A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15743009P 2009-03-04 2009-03-04
US25974309P 2009-11-10 2009-11-10
PCT/US2010/024871 WO2010101724A1 (en) 2009-03-04 2010-02-22 Imidazole derivatives useful as modulators of faah and as faah imaging agents

Publications (1)

Publication Number Publication Date
MX2011009224A true MX2011009224A (es) 2011-09-28

Family

ID=42709958

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009224A MX2011009224A (es) 2009-03-04 2010-02-22 Derivados de imidazol utiles como modulares de amida hidrolasa de acido graso y como agentes de formacion de imagenes de amida hidrolasa de cido graso.

Country Status (8)

Country Link
US (1) US8664253B2 (es)
EP (1) EP2403338B1 (es)
JP (1) JP5667093B2 (es)
CN (1) CN102413694B (es)
AU (1) AU2010221650B2 (es)
CA (1) CA2753972A1 (es)
MX (1) MX2011009224A (es)
WO (1) WO2010101724A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150166528A1 (en) 2012-06-14 2015-06-18 Basf Se Pesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests
CN110804048A (zh) * 2019-11-08 2020-02-18 暨南大学 恶唑酮类化合物及其应用、faah的正电子药物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426360B1 (en) * 1994-07-28 2002-07-30 G D Searle & Co. 4,5-substituted imidazolyl compounds for the treatment of inflammation
JP2000109467A (ja) * 1998-10-05 2000-04-18 Sumitomo Pharmaceut Co Ltd イミダゾール誘導体を含有する医薬
AU2039800A (en) * 1998-12-04 2000-06-26 Ontogen Corporation 5-membered heterocycles for the treatment of human diseases involving modulatorsof selectins
WO2005086895A2 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
WO2005100322A1 (en) * 2004-04-14 2005-10-27 Pfizer Limited Sulphur-linked imidazole compounds for the treament of hiv
US7709654B2 (en) * 2006-09-11 2010-05-04 Board Of Trustees Of Michigan State University Process for producing oxazole, imidazole, pyrrazole boryl compounds
PT2275352E (pt) * 2008-04-10 2012-07-13 Papeles Y Cartones De Europa S A Embalagem para peixe fresco e produtos similares
US20110144056A1 (en) * 2008-06-11 2011-06-16 Lin Linus S Pyrazole derivatives useful as inhibitors of faah
CA2727245A1 (en) * 2008-06-11 2009-12-17 Merck Sharp & Dohme Corp. Imidazole derivatives useful as inhibitors of faah
AU2009279874B2 (en) * 2008-08-04 2015-02-12 Merck Sharp & Dohme Corp. Oxazole derivatives useful as inhibitors of FAAH

Also Published As

Publication number Publication date
EP2403338B1 (en) 2017-07-26
CN102413694A (zh) 2012-04-11
AU2010221650B2 (en) 2015-06-25
JP5667093B2 (ja) 2015-02-12
US8664253B2 (en) 2014-03-04
EP2403338A4 (en) 2013-08-21
WO2010101724A1 (en) 2010-09-10
CA2753972A1 (en) 2010-09-10
US20120115894A1 (en) 2012-05-10
AU2010221650A1 (en) 2011-10-13
CN102413694B (zh) 2014-12-10
EP2403338A1 (en) 2012-01-11
JP2012519687A (ja) 2012-08-30

Similar Documents

Publication Publication Date Title
EP2593102A4 (en) OXAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH
BR112012023974A2 (pt) composto, composição farmacêutica, método de tratar uma doença mediada com faah, e, uso de um composto.
BR112012028055A2 (pt) composto, uso do mesmo, composição farmacêutica, e, métodos de tratar uma doença mediada
TW200740801A (en) N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
MX2012008801A (es) Composiciones farmaceuticas para el tratamiento de dolor y otras indicaciones.
NZ610689A (en) Substituted 6-amino-nicotinamides as kcnq2/3 modulators
MX349992B (es) Composiciones de alta concentracion de alfa-glucosidasa para el tratamiento de la enfermedad de pompe.
WO2007061862A3 (en) 2-keto-oxazoles as modulators of fatty acid amide hydrolase
EA200970296A1 (ru) Содержащие диариловый эфир соединения мочевины
TW200635912A (en) Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
PH12014501677B1 (en) 5-membered heterocyclic amides and related compounds
MY148461A (en) Heteroaryl amide analogues as p2x7 antagonists
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
MXPA05006123A (es) Analogos de quinazolin-4-ilamina 2-sustituida como moduladores de receptores de capsaicina.
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
MA33295B1 (fr) Nouvelle formulation de diclofénac
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
MX2012007013A (es) Moduladores alostericos positivos de receptores m1 de la quinolina amida.
HK1152883A1 (en) Formulation and method for the prevention and treatment of bone metastases or other bone diseases
WO2007140005A3 (en) Oxazolyl piperidine modulators of fatty acid amide hydrolase
WO2007098142A3 (en) Oxazole ketones as modulators of fatty acid amide hydrolase
WO2008153752A3 (en) Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
TW200510373A (en) Substituted quinolin-4-ylamine analogues
CL2011001428A1 (es) Compuestos derivados de amidas del acido tetrahidroisoquinolil-4-oxobutirico; composicion farmaceutica; y uso en el tratamiento de desordenes o enfermedades mediadas por canales de potasio kcnq2/3, tales como dolor, epilepsia. incontinencia urinaria, ansiedad, entre otras.
TW200621251A (en) Substituted biaryl quinolin-4-ylamine analogues

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: MERCK SHARP & DOHME CORP.*

HC Change of company name or juridical status

Owner name: MERCK SHARP & DOHME CORP.*

FG Grant or registration